The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Discovery And Development Of Novel Venom Peptide Analgesics
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Professor Lewis will discover and develop new research tools and potential therapeutics from toxins acting on pain pathways. The Fellowship will leverage (i) well-funded collaborations with top Australian and international scientists (ii) the recently established IMB Centre for Pain Research that I lead as inaugural Director, and (iii) an outstanding Institute equipped with leading edge technologies for high throughput and high content discovery and proteomic and transcriptomic analysis.
Stroke is a devastating disease causing mortality and morbidity on a massive scale, and which still has no treatment besides a clot-buster that cannot be used in 90% of patients. This research should provide a better understanding of stroke pathology and identify new therapeutic directions. It will elucidate an unappreciated but crucial role of specific immune cells in brain injury after stroke, and hopefully lead to new ways to limit brain injury and promote recovery from stroke.
Biomedical Investigations Of Pharmacology And Pathology For Disease Treatment
Funder
National Health and Medical Research Council
Funding Amount
$863,413.00
Summary
I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of ....I am an NHMRC SPRF & Director of the Molecular Pharmacology & Pathology Program consisting of 34 researchers. The breadth of our studies is diverse & continues to expand. Excitingly, we have recently obtained commercialisation support to develop our anti-tumour drug, DpC. My vision for the next 5 yrs is to direct development of these agents together with investigations of basic mechanism. These studies will be done with a team of outstanding researchers I am mentoring and an established group of experienced collaborators.Read moreRead less
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
Integrated Approaches To Targeting G Protein-coupled Receptors: Translational Studies Of Novel Drug-receptor Paradigms
Funder
National Health and Medical Research Council
Funding Amount
$851,980.00
Summary
This Fellowship focuses on one of the largest family of proteins found in the human body, the so-called ‘G protein-coupled receptors ‘ (GPCRs). GPCRs control how each of our cells communicates with one another, and have been implicated in virtually all diseases. This proposal will study new mechanisms of targeting drugs to GPCRs that can overcome current drug discovery bottlenecks and lead to new ways of treating neuropsychiatric, cardiovascular, inflammatory and metabolic diseases.
Research Fellowship: Understanding G Protein-coupled Receptors (GPCRs)
Funder
National Health and Medical Research Council
Funding Amount
$444,177.00
Summary
This project focuses on drug action at G protein-coupled receptors (GPCRs), the largest class of drug targets. It builds on key discoveries by the applicant that novel sites on GPCRs can be targeted by small molecules in a selective manner, thus minimizing side effects and maximizing therapeutic efficacy. Because this approach can work across most GPCR families, the relevance to the pharmaceutical industry and GPCR-related diseases, such as schizophrenia and diabetes, is very high.
Relaxin family peptides are small proteins that have numerous essential biological roles in the vascular system, brain and gut. The hormone relaxin is currently in Phase III clinical trials to treat heart failure and the other peptides show great potential as drugs to treat diseases including mental illnesses and obesity. My research focuses on developing drugs targeting the receptors for these important peptide systems and understanding how these drugs can be best used therapeutically
Increasing Value, Reducing Waste From Incomplete Or Unusable Reports Of Medical Research
Funder
National Health and Medical Research Council
Funding Amount
$788,486.00
Summary
We estimated that the avoidable waste in research - from design flaws, non-publication, and inadequate reporting - results in over $85 Billion annual loss. I will research innovations to reduce this waste. My focus is particularly on non-drug interventions - exercises, dietary changes, self-monitoring, e-health applications – which are often effective but more difficult to use in clinical practice, and being compiled in my recently founded Handbook of Non-Drug Interventions (see RACGP website).
Pathophysiology And Treatment Of Malaria In Our Region
Funder
National Health and Medical Research Council
Funding Amount
$951,005.00
Summary
Malaria continues to kill 420,000 people/year. I will lead a team of clinical scientists in identifying how each of the different malaria parasites cause damage to small blood vessels, kidneys and other organs, and will test whether two different drugs can improve these processes and reduce illness. Many of my previous research findings have changed malaria treatment in Australia and across SE Asia, and, where appropriate, I will use new research findings to improve treatments.
Molecular Mechanisms And Pharmacology Of The Dynamins
Funder
National Health and Medical Research Council
Funding Amount
$883,375.00
Summary
His research focuses on the molecular mechanisms of synaptic transmission in the nervous system to: a) understand the basic science of nerve communication and b) develop drugs to control diseases of nerve terminals like epilepsy. The main focus is on proteins called the dynamins, which are self-assembling molecular machines acting in many intracellular functions. There are three dynamin genes: dynI, II and III with diverse functions in the different parts of the body.